WO2005023261A1 - 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses - Google Patents

1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses Download PDF

Info

Publication number
WO2005023261A1
WO2005023261A1 PCT/EP2004/009699 EP2004009699W WO2005023261A1 WO 2005023261 A1 WO2005023261 A1 WO 2005023261A1 EP 2004009699 W EP2004009699 W EP 2004009699W WO 2005023261 A1 WO2005023261 A1 WO 2005023261A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
fluoro
alkyl
piperazine
halogen
Prior art date
Application number
PCT/EP2004/009699
Other languages
English (en)
French (fr)
Inventor
Daniela Alberati-Giani
Synese Jolidon
Robert Narquizian
Matthias Heinrich Nettekoven
Roger David Norcross
Emmanuel Pinard
Henri Stalder
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04764664A priority Critical patent/EP1703909B1/en
Priority to NZ545613A priority patent/NZ545613A/en
Priority to SI200431126T priority patent/SI1703909T1/sl
Priority to DE602004020674T priority patent/DE602004020674D1/de
Priority to DK04764664T priority patent/DK1703909T3/da
Priority to BRPI0413536A priority patent/BRPI0413536B8/pt
Priority to AT04764664T priority patent/ATE428424T1/de
Priority to JP2006525700A priority patent/JP4563387B2/ja
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to MXPA06002672A priority patent/MXPA06002672A/es
Priority to CA2538135A priority patent/CA2538135C/en
Priority to PL04764664T priority patent/PL1703909T3/pl
Priority to AU2004269892A priority patent/AU2004269892B2/en
Publication of WO2005023261A1 publication Critical patent/WO2005023261A1/en
Priority to NO20060975A priority patent/NO20060975L/no
Priority to IL174075A priority patent/IL174075A/en
Priority to HK07105684.3A priority patent/HK1100483A1/xx
Priority to HR20090265T priority patent/HRP20090265T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
PCT/EP2004/009699 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses WO2005023261A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MXPA06002672A MXPA06002672A (es) 2003-09-09 2004-08-31 Derivados de 1-benzoil-piperazina como inhibidores de absorcion de glicina para el tratamiento de psicosis.
NZ545613A NZ545613A (en) 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
CA2538135A CA2538135C (en) 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
DK04764664T DK1703909T3 (da) 2003-09-09 2004-08-31 1-benzoyl-piperazinderivater som glycinoptagelsesinhibitorer til behandling af psykoser
BRPI0413536A BRPI0413536B8 (pt) 2003-09-09 2004-08-31 derivados de 1-benzoil-piperazina, seu uso e medicamento que os compreende
AT04764664T ATE428424T1 (de) 2003-09-09 2004-08-31 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
JP2006525700A JP4563387B2 (ja) 2003-09-09 2004-08-31 精神病の処置のためのグリシン取り込み阻害剤としての１−ベンゾイル−ピペラジン誘導体
EP04764664A EP1703909B1 (en) 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
SI200431126T SI1703909T1 (sl) 2003-09-09 2004-08-31 Derivati 1-benzoil-piperazina kot inhibitorji vnosa glicina za zdravljenje psihoz
DE602004020674T DE602004020674D1 (de) 2003-09-09 2004-08-31 1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
PL04764664T PL1703909T3 (pl) 2003-09-09 2004-08-31 Pochodne 1-benzoilopiperazyny jako inhibitory wychwytu glicyny do leczenia psychoz
AU2004269892A AU2004269892B2 (en) 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
NO20060975A NO20060975L (no) 2003-09-09 2006-02-28 1-Benzoyl-piperazinderivater som glycin gjenopptaksinhibitorer for behandling av psykoser
IL174075A IL174075A (en) 2003-09-09 2006-03-02 Derivatives of 1-benzoyl-piperazine as glycine absorption inhibitors for the treatment of psychosis
HK07105684.3A HK1100483A1 (en) 2003-09-09 2007-05-29 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
HR20090265T HRP20090265T1 (en) 2003-09-09 2009-05-12 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019682 2003-09-09
EP03019682.8 2003-09-09

Publications (1)

Publication Number Publication Date
WO2005023261A1 true WO2005023261A1 (en) 2005-03-17

Family

ID=34259148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009699 WO2005023261A1 (en) 2003-09-09 2004-08-31 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Country Status (28)

Country Link
US (1) US7462617B2 (US20050059668A1-20050317-C00173.png)
EP (1) EP1703909B1 (US20050059668A1-20050317-C00173.png)
JP (1) JP4563387B2 (US20050059668A1-20050317-C00173.png)
KR (1) KR100774621B1 (US20050059668A1-20050317-C00173.png)
CN (1) CN100522171C (US20050059668A1-20050317-C00173.png)
AR (1) AR045587A1 (US20050059668A1-20050317-C00173.png)
AT (1) ATE428424T1 (US20050059668A1-20050317-C00173.png)
AU (1) AU2004269892B2 (US20050059668A1-20050317-C00173.png)
BR (1) BRPI0413536B8 (US20050059668A1-20050317-C00173.png)
CA (1) CA2538135C (US20050059668A1-20050317-C00173.png)
CO (1) CO5680430A2 (US20050059668A1-20050317-C00173.png)
DE (1) DE602004020674D1 (US20050059668A1-20050317-C00173.png)
DK (1) DK1703909T3 (US20050059668A1-20050317-C00173.png)
ES (1) ES2322651T3 (US20050059668A1-20050317-C00173.png)
HK (1) HK1100483A1 (US20050059668A1-20050317-C00173.png)
HR (1) HRP20090265T1 (US20050059668A1-20050317-C00173.png)
IL (1) IL174075A (US20050059668A1-20050317-C00173.png)
MX (1) MXPA06002672A (US20050059668A1-20050317-C00173.png)
MY (1) MY140470A (US20050059668A1-20050317-C00173.png)
NO (1) NO20060975L (US20050059668A1-20050317-C00173.png)
NZ (1) NZ545613A (US20050059668A1-20050317-C00173.png)
PL (1) PL1703909T3 (US20050059668A1-20050317-C00173.png)
PT (1) PT1703909E (US20050059668A1-20050317-C00173.png)
RU (1) RU2355683C2 (US20050059668A1-20050317-C00173.png)
SI (1) SI1703909T1 (US20050059668A1-20050317-C00173.png)
TW (1) TW200526601A (US20050059668A1-20050317-C00173.png)
WO (1) WO2005023261A1 (US20050059668A1-20050317-C00173.png)
ZA (1) ZA200601988B (US20050059668A1-20050317-C00173.png)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063709A1 (en) * 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
WO2007147770A2 (en) 2006-06-22 2007-12-27 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
EP1871165A2 (en) * 2005-04-11 2008-01-02 Yale University Corporation Method of treating schizophrenia prodrome
WO2008069997A1 (en) * 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
DE602004009323T2 (de) * 2003-09-09 2008-07-10 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
BRPI0515477A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
US20080167321A1 (en) * 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
PT1828154E (pt) * 2004-12-09 2009-06-08 Hoffmann La Roche Derivados de fenil-piperazina-metanona
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
ATE435650T1 (de) * 2005-01-18 2009-07-15 Hoffmann La Roche 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen
DE602006010175D1 (de) * 2005-01-26 2009-12-17 Hoffmann La Roche Phenylmethanonderivate und ihre verwendung als glycin-transporter-1-hemmer
ES2334578T3 (es) * 2005-02-07 2010-03-12 F. Hoffmann-La Roche Ag Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina.
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
UA100974C2 (ru) * 2006-12-01 2013-02-25 Мерк Шарп Энд Доме Корп. Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
BRPI0820972A2 (pt) 2007-12-11 2018-08-14 Hoffmann La Roche compostos inibidores de estearoil-coa dessaturase 1, processo para a sua preparação, composição farmacêutica que compreende, uso dos mesmos e método para o tratamento e profilaxia de obesidade.
JP5219086B2 (ja) * 2009-03-24 2013-06-26 国立大学法人九州大学 トリフルオロメチルアレーン類の製造方法
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
CN105814035B (zh) 2013-12-13 2018-02-02 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
US9708334B2 (en) 2014-04-24 2017-07-18 Dart Neuroscience (Cayman) Ltd. Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
CN112225728A (zh) * 2020-08-18 2021-01-15 四川农业大学 一种多取代苯甲酰胺化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
EP0624584A1 (en) * 1993-05-14 1994-11-17 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives useful as calmodolin inhibitors
WO1999044596A2 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
WO2004037800A1 (en) * 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
ES2297458T3 (es) * 2003-08-11 2008-05-01 F. Hoffmann-La Roche Ag Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti.
DE602004009323T2 (de) * 2003-09-09 2008-07-10 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
EP0624584A1 (en) * 1993-05-14 1994-11-17 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives useful as calmodolin inhibitors
WO1999044596A2 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
WO2004037800A1 (en) * 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 2004 (2004-01-01), XP002309007, Database accession no. 2004:660630 CHEMCATS *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 9 May 2003 (2003-05-09), XP002308978, Database accession no. 2002:330684 CHEMCATS *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 July 2003 (2003-07-10), XP002308991, Database accession no. CAS RN: 545440-93-5 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 October 2001 (2001-10-10), XP002308979, Database accession no. CAS RN: 310415-30-6 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 11 July 2003 (2003-07-11), XP002308992, Database accession no. CAS RN: 546106-54-1 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 11 July 2003 (2003-07-11), XP002308993, Database accession no. CAS RN: 546120-27-8 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 January 2002 (2002-01-22), XP002308983, Database accession no. CAS RN: 385380-98-3 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 June 2002 (2002-06-22), XP002308989, Database accession no. CAS RN: 433242-97-8 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 24 April 2002 (2002-04-24), XP002308984, Database accession no. CAS RN: 406917-15-5 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 26 June 2002 (2002-06-26), XP002308990, Database accession no. CAS RN: 433701-63-4 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 June 2002 (2002-06-03), XP002308985, Database accession no. CAS RN: 424802-45-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 June 2002 (2002-06-03), XP002308986, Database accession no. CAS RN: 424804-07-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 June 2002 (2002-06-03), XP002308987, Database accession no. CAS RN: 424805-07-2 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 June 2002 (2002-06-03), XP002308988, Database accession no. CAS RN: 424817-79-8 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 August 2001 (2001-08-04), XP002308980, Database accession no. CAS RN: 349615-45-8 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 9 January 2002 (2002-01-09), XP002308981, Database accession no. CAS RN: 381184-27-6 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7375226B2 (en) 2004-12-15 2008-05-20 Hoffman-La Roche Inc. Bi- and tricyclic substituted phenyl methanones
WO2006063709A1 (en) * 2004-12-15 2006-06-22 F.Hoffmann-La Roche Ag Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
US7220744B2 (en) 2005-01-07 2007-05-22 Hoffman-La Roche Inc. Monocyclic substituted phenyl methanones
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
EP1871165A4 (en) * 2005-04-11 2009-10-21 Yale University Corp METHOD OF TREATING A SCHIZOPHRENIC PRODROME
US8492418B2 (en) 2005-04-11 2013-07-23 Yale University Method of treating schizophrenia prodrome
EP1871165A2 (en) * 2005-04-11 2008-01-02 Yale University Corporation Method of treating schizophrenia prodrome
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
AU2007263083B2 (en) * 2006-06-22 2012-10-04 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
CN101472886B (zh) * 2006-06-22 2011-07-13 弗·哈夫曼-拉罗切有限公司 取代的苯基甲酮衍生物
KR101072796B1 (ko) 2006-06-22 2011-10-14 에프. 호프만-라 로슈 아게 치환된 페닐 메탄온 유도체
JP2009541251A (ja) * 2006-06-22 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルメタノン誘導体
US7951836B2 (en) 2006-06-22 2011-05-31 Hoffmann-La Roche Inc. Substituted phenyl methanone derivatives
WO2007147770A3 (en) * 2006-06-22 2008-05-22 Hoffmann La Roche Substituted phenyl methanone derivatives
WO2007147770A2 (en) 2006-06-22 2007-12-27 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
NO342586B1 (no) * 2006-12-01 2018-06-18 Merck Sharp & Dohme Substituerte diazepanforbindelser som oreksinreseptorantagonister, og deres anvendelse innen medisin samt farmasøytisk preparat derav
US7951797B2 (en) 2006-12-01 2011-05-31 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
JP2010511621A (ja) * 2006-12-01 2010-04-15 メルク エンド カムパニー インコーポレーテッド オレキシンレセプターアンタゴニストとしての置換ジアゼパン化合物
EP2392572A1 (en) * 2006-12-01 2011-12-07 Merck Sharp & Dohme Corp. Substituted diazepan compounds as orexin receptor antagonists
WO2008069997A1 (en) * 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
RU2561727C2 (ru) * 2006-12-01 2015-09-10 Мерк Шарп И Доум Корп. Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8957089B2 (en) 2008-04-01 2015-02-17 AbbVie Deutschland GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9096619B2 (en) 2009-02-16 2015-08-04 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9067871B2 (en) 2009-02-16 2015-06-30 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
KR20060087550A (ko) 2006-08-02
CN100522171C (zh) 2009-08-05
NO20060975L (no) 2006-04-06
AU2004269892A1 (en) 2005-03-17
JP2007505062A (ja) 2007-03-08
AU2004269892B2 (en) 2010-03-11
EP1703909A1 (en) 2006-09-27
PL1703909T3 (pl) 2009-09-30
CA2538135C (en) 2015-01-27
BRPI0413536A (pt) 2006-10-10
HK1100483A1 (en) 2007-09-21
JP4563387B2 (ja) 2010-10-13
MY140470A (en) 2009-12-31
TW200526601A (en) 2005-08-16
AR045587A1 (es) 2005-11-02
ES2322651T3 (es) 2009-06-24
CA2538135A1 (en) 2005-03-17
ZA200601988B (en) 2007-05-30
BRPI0413536B1 (pt) 2019-03-19
RU2355683C2 (ru) 2009-05-20
CO5680430A2 (es) 2006-09-29
IL174075A (en) 2011-12-29
BRPI0413536B8 (pt) 2021-05-25
PT1703909E (pt) 2009-05-27
HRP20090265T1 (en) 2009-06-30
MXPA06002672A (es) 2006-06-06
US20050059668A1 (en) 2005-03-17
SI1703909T1 (sl) 2009-08-31
NZ545613A (en) 2009-11-27
IL174075A0 (en) 2006-08-01
RU2006111582A (ru) 2007-10-27
ATE428424T1 (de) 2009-05-15
DK1703909T3 (da) 2009-06-22
CN1878554A (zh) 2006-12-13
EP1703909B1 (en) 2009-04-15
DE602004020674D1 (de) 2009-05-28
KR100774621B1 (ko) 2007-11-14
US7462617B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
EP1703909A1 (en) 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
JP4252598B2 (ja) Ｏｒ置換フェニル基を有するピペラジン及びｇｌｙｔ１阻害剤としてのこれらの使用
AU2004269889B2 (en) 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
US20080287455A1 (en) Sulfanyl substituted phenyl methanones
IL184206A (en) Benzoyl-tetrahydropyridine derivatives as glyt-1 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032874.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: GB0506257.5

Country of ref document: GB

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004764664

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 545613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 174075

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12006500478

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 812/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/01988

Country of ref document: ZA

Ref document number: 2538135

Country of ref document: CA

Ref document number: 06023405

Country of ref document: CO

Ref document number: 200601988

Country of ref document: ZA

Ref document number: PA/a/2006/002672

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004269892

Country of ref document: AU

Ref document number: 2006525700

Country of ref document: JP

Ref document number: 1020067004873

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004269892

Country of ref document: AU

Date of ref document: 20040831

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004269892

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006111582

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067004873

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004764664

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413536

Country of ref document: BR